Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist.
Article
in English
| IMSEAR
| ID: sea-39090
ABSTRACT
PURPOSE:
To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK).DESIGN:
A prospective randomized controlled clinical study.PARTICIPANTS:
Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital. INTERVENTION Patients received two drops of ketorolac tromethamine in one eye immediately after surgery. MAIN OUTCOMEMEASURES:
Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours.RESULTS:
There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes.CONCLUSIONS:
Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Astigmatism
/
Pain Measurement
/
Female
/
Humans
/
Male
/
Anti-Inflammatory Agents, Non-Steroidal
/
Prospective Studies
/
Adult
/
Ketorolac Tromethamine
/
Keratomileusis, Laser In Situ
Type of study:
Controlled clinical trial
/
Observational study
Language:
English
Year:
2001
Type:
Article
Similar
MEDLINE
...
LILACS
LIS